#1 Clinical Trials Search in Europe

Tecaginlimab

Tecaginlimab, also known as GEN1042 or DuoBody-CD40x4-1BB, is an investigational drug being studied in clinical trials for patients with advanced solid tumors. These trials aim to evaluate the safety, tolerability, and anti-tumor activity of Tecaginlimab when used alone or in combination with other treatments, including pembrolizumab, chemotherapy, and radiotherapy. The studies focus on patients with various types of advanced solid tumors, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.

Table of Contents

What is TECAGINLIMAB?

TECAGINLIMAB is a new and innovative medication being studied for the treatment of advanced solid tumors. It is also known by several other names, including GEN1042, DuoBody-CD40x4-1BB, BNT-312, and “humanised IgG1 monoclonal antibody against CD40 and 4-1BB”[1]. This drug is currently undergoing clinical trials to evaluate its safety and effectiveness in treating various types of cancer.

How Does TECAGINLIMAB Work?

TECAGINLIMAB is a type of medication called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses or cancer cells. In the case of TECAGINLIMAB, it is designed to target two specific proteins in the body: CD40 and 4-1BB (also known as CD137)[1]. These proteins play important roles in regulating the immune system’s response to cancer.

By targeting both CD40 and 4-1BB, TECAGINLIMAB aims to enhance the body’s natural immune response against cancer cells. This dual-targeting approach is why it’s sometimes referred to as a “DuoBody” medication[1].

What Conditions Does TECAGINLIMAB Treat?

TECAGINLIMAB is being studied for the treatment of various types of advanced solid tumors. Specifically, it is being investigated for use in patients with[1]:

  • Relapsed or refractory (difficult to treat) advanced and/or metastatic melanoma (a type of skin cancer)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Head and neck squamous cell carcinoma (HNSCC)
  • Pancreatic ductal adenocarcinoma (PDAC, a type of pancreatic cancer)
  • Colorectal Cancer (CRC)

These conditions are all considered malignant solid tumors, which means they are cancerous growths that form masses of tissue. The term “advanced” typically means that the cancer has spread from its original location to other parts of the body[1][2].

Clinical Trials and Research

TECAGINLIMAB is currently being studied in clinical trials to determine its safety and effectiveness. These trials are typically divided into phases:

  1. Phase I/II trial: This trial aims to determine the safe dosage of TECAGINLIMAB and evaluate its initial effectiveness. Researchers are looking at how well the drug works on its own and in combination with other treatments like pembrolizumab (another immunotherapy drug) and chemotherapy[1].
  2. Phase I dose finding and Phase II trial: This study is investigating the use of TECAGINLIMAB in combination with radiotherapy, with or without pembrolizumab. The goal is to determine the best dose and evaluate how well this combination works in treating metastatic solid tumors[2].

Potential Benefits

While the research is still ongoing, scientists are hopeful that TECAGINLIMAB could offer several potential benefits for cancer patients:

  • Anti-tumor activity: The main goal of the treatment is to shrink or slow the growth of tumors[1][2].
  • Improved response to other treatments: When used in combination with other therapies like radiotherapy or other immunotherapy drugs, TECAGINLIMAB might enhance the overall effectiveness of treatment[2].
  • Potential for long-lasting responses: Researchers are studying how long the beneficial effects of the treatment might last[1].

Safety and Side Effects

As with any new medication, understanding the safety profile and potential side effects of TECAGINLIMAB is a crucial part of the ongoing research. The clinical trials are closely monitoring for any adverse events (side effects) that patients might experience[1][2].

It’s important to note that because TECAGINLIMAB works by altering the immune system, there may be a risk of immune-related side effects. Patients with active, known, or suspected autoimmune diseases may not be eligible for treatment with this drug[2].

Administration

TECAGINLIMAB is administered as an intravenous infusion. This means it is given directly into a vein, typically through a drip. The exact dosage and frequency of administration are still being determined through the clinical trials[1][2].

Who is Eligible for TECAGINLIMAB Treatment?

As TECAGINLIMAB is still in the clinical trial phase, it is not yet widely available for general use. Eligibility for the current trials typically includes[2]:

  • Adults (18 years or older) with confirmed metastatic solid tumors
  • Patients for whom standard therapies are no longer effective or available
  • Individuals with measurable disease according to specific criteria (RECIST v1.1)
  • Patients with a life expectancy of more than 3 months
  • Those with adequate liver, kidney, heart, and bone marrow function

It’s important to note that these criteria may vary depending on the specific clinical trial, and there are also several exclusion criteria that might make someone ineligible for the treatment[2].

Aspect Details
Drug Name Tecaginlimab (GEN1042, DuoBody-CD40x4-1BB)
Drug Type Humanized IgG1 monoclonal antibody targeting CD40 and 4-1BB
Administration Intravenous infusion
Cancer Types Studied Advanced solid tumors (melanoma, NSCLC, HNSCC, PDAC, CRC)
Trial Phases Phase I/II
Treatment Approaches Monotherapy, combination with pembrolizumab, chemotherapy, radiotherapy
Primary Objectives Determine MTD/RP2D, evaluate safety and anti-tumor activity
Key Endpoints ORR, DOR, DCR, PFS, OS, safety, PK, immunogenicity
Special Focus Abscopal response in combination with radiotherapy

FAQ

  • What is Tecaginlimab? Tecaginlimab, also known as GEN1042 or DuoBody-CD40x4-1BB, is an investigational drug being studied for the treatment of advanced solid tumors. It is a humanized IgG1 monoclonal antibody that targets both CD40 and 4-1BB proteins.
  • What types of cancer is Tecaginlimab being studied for? Tecaginlimab is being studied for various types of advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).
  • How is Tecaginlimab administered in clinical trials? Tecaginlimab is administered intravenously (through a vein) in clinical trials. It is being studied both as a monotherapy and in combination with other treatments such as pembrolizumab, chemotherapy, and radiotherapy.
  • What are the main objectives of the Tecaginlimab clinical trials? The main objectives of the Tecaginlimab clinical trials are to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), evaluate the safety and tolerability of the drug, assess its anti-tumor activity, and characterize its pharmacokinetics and immunogenicity.
  • What are some of the key endpoints being measured in these trials? Key endpoints being measured in the Tecaginlimab trials include objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and the incidence and severity of adverse events. Some trials also measure abscopal response in non-irradiated target lesions when combined with radiotherapy.

Ongoing Clinical Trials on Tecaginlimab

  • Study on the Safety and Effectiveness of Tecaginlimab and Pembrolizumab with Radiotherapy for Patients with Metastatic Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Germany Italy Spain

Glossary

  • Tecaginlimab: An investigational drug, also known as GEN1042 or DuoBody-CD40x4-1BB, being studied for the treatment of advanced solid tumors. It is a humanized IgG1 monoclonal antibody targeting CD40 and 4-1BB proteins.
  • Monotherapy: A type of treatment where a single drug is used alone to treat a condition.
  • Combination Therapy: A treatment approach that uses two or more drugs or therapies together to treat a condition.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be safe and potentially effective, which is then used in further clinical trials.
  • Dose-Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Disease Control Rate (DCR): The percentage of patients whose cancer shrinks or remains stable in response to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients diagnosed with a disease are still alive.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Anti-Drug Antibodies (ADAs): Antibodies produced by the body's immune system in response to a therapeutic drug, which can potentially reduce the drug's effectiveness.
  • Abscopal Response: A phenomenon in cancer treatment where localized treatment of a tumor causes shrinkage of tumors in other parts of the body.
  • Immunoradiotherapy: A treatment approach that combines immunotherapy (which helps the immune system fight cancer) with radiotherapy (which uses radiation to kill cancer cells).

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-anti-tumor-effects-of-gen1042-alone-or-with-pembrolizumab-and-chemotherapy-in-patients-with-advanced-solid-tumors/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tecaginlimab-and-pembrolizumab-with-radiotherapy-for-patients-with-metastatic-solid-tumors/